Cytodyn Inc
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colo… Read more
Market Cap & Net Worth: Cytodyn Inc (CYDY)
Cytodyn Inc (OTCQB:CYDY) has a market capitalization of $266.78 Million ($266.78 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #13460 globally and #5575 in its home market, demonstrating a -8.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cytodyn Inc's stock price $0.21 by its total outstanding shares 1270395000 (1.27 Billion).
Cytodyn Inc Market Cap History: 2015 to 2025
Cytodyn Inc's market capitalization history from 2015 to 2025. Data shows change from $978.20 Million to $266.78 Million (-13.62% CAGR).
Cytodyn Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cytodyn Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1098.46x
Cytodyn Inc's market cap is 1098.46 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.26 Billion | $-4.39 Million | -$154.67 Million | -286.69x | N/A |
| 2022 | $292.19 Million | $266.00K | -$210.82 Million | 1098.46x | N/A |
Competitor Companies of CYDY by Market Capitalization
Companies near Cytodyn Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Cytodyn Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Cytodyn Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Cytodyn Inc's market cap moved from $978.20 Million to $ 266.78 Million, with a yearly change of -13.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $266.78 Million | +90.91% |
| 2024 | $139.74 Million | -45.00% |
| 2023 | $254.08 Million | -13.04% |
| 2022 | $292.19 Million | -76.77% |
| 2021 | $1.26 Billion | -81.63% |
| 2020 | $6.85 Billion | +439.00% |
| 2019 | $1.27 Billion | +112.77% |
| 2018 | $597.09 Million | -14.64% |
| 2017 | $699.48 Million | -17.85% |
| 2016 | $851.42 Million | -12.96% |
| 2015 | $978.20 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Cytodyn Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $266.78 Million USD |
| MoneyControl | $266.78 Million USD |
| MarketWatch | $266.78 Million USD |
| marketcap.company | $266.78 Million USD |
| Reuters | $266.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.